Research programme: galectin modulators - Galecto Biotech

Drug Profile

Research programme: galectin modulators - Galecto Biotech

Alternative Names: Galectin activators - Galecto Biotech; Galectin inhibitors - Galecto Biotech; Galectin-3 inhibitors - Galecto Biotech

Latest Information Update: 05 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galecto Biotech
  • Class Small molecules
  • Mechanism of Action Galectin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Fibrosis; Inflammation

Most Recent Events

  • 03 Nov 2014 Bristol Myers-Squibb gains exclusive option to acquire Galecto Biotech
  • 30 Jan 2014 Early research in Cancer in Sweden (unspecified route)
  • 30 Jan 2014 Early research in Inflammation in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top